Fox Run Management L.l.c. adds Regeneron Pharmaceuticals Inc (REGN) to its portfolio

Regeneron Pharmaceuticals Inc (REGN) : Fox Run Management L.l.c. added new position in Regeneron Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 2,700 shares of Regeneron Pharmaceuticals Inc which is valued at $1,091,826 , the company said in a statement filed on Apr 18, 2016 with the SEC.Regeneron Pharmaceuticals Inc makes up approximately 0.70% of Fox Run Management L.l.c.’s portfolio.

Regeneron Pharmaceuticals Inc closed down -5.19 points or -1.27% at $404.38 with 8,49,430 shares getting traded on Friday. Post opening the session at $406.61, the shares hit an intraday low of $394.5 and an intraday high of $411.576 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Other Hedge Funds, Including , Gateway Investment Advisers reduced its stake in REGN by selling 2,576 shares or 28.9% in the most recent quarter. The Hedge Fund company now holds 6,336 shares of REGN which is valued at $2,562,152. Regeneron Pharmaceuticals Inc makes up approx 0.02% of Gateway Investment Advisers’s portfolio. Santa Fe Partners sold out all of its stake in REGN during the most recent quarter. The investment firm sold 7,471 shares of REGN which is valued $3,038,680.Livforsakringsbolaget Skandia Omsesidigt reduced its stake in REGN by selling 1,500 shares or 18.35% in the most recent quarter. The Hedge Fund company now holds 6,676 shares of REGN which is valued at $2,715,329. Regeneron Pharmaceuticals Inc makes up approx 0.13% of Livforsakringsbolaget Skandia Omsesidigt’s portfolio.

On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.50 based on the information available during the earnings call on Feb 9, 2016. Analyst had a consensus of $3.33. The company had revenue of $1098.00 million for the quarter, compared to analysts expectations of $1171.42 million. The company’s revenue was up 36.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.79 EPS.

Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc was Downgraded by Wells Fargo to ” Market Perform” on Apr 20, 2016. Shares were Reiterated by Sun Trust Rbsn Humphrey on Mar 17, 2016 to “Neutral” and Lowered the Price Target to $ 410 from a previous price target of $450 .Shares were Downgraded by Chardan Capital Markets on Mar 16, 2016 to ” Sell” and Lowered the Price Target to $ 325 from a previous price target of $375 .

Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.

Leave a Reply

Regeneron Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Regeneron Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.